Editas Medicine, Inc. (EDIT) vs Kyverna Therapeutics, Inc. (KYTX)

Editas Medicine, Inc. and Kyverna Therapeutics, Inc. are both Biotechnology companies. Editas Medicine, Inc. and Kyverna Therapeutics, Inc. are of similar size ($432.3M and $430.0M). Kyverna Therapeutics, Inc. has the higher net margin (0.00% vs −157.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Kyverna Therapeutics, Inc. leads on 7 and Editas Medicine, Inc. on 5.

Valuation

Metric EDIT KYTX Biotechnology median
P/E n/m n/m 7.88
P/S 6.55 n/m 11.47
P/B 2.92 2.51 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 2.58 n/m 10.73
Earnings yield (29.07%) (43.17%) (28.84%)
Free cash flow yield (39.08%) (38.34%) (23.03%)

Profitability

Metric EDIT KYTX Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (161.39%) 0.00% 0.00%
Net margin (157.32%) 0.00% 0.00%
Free cash flow margin (255.88%) 0.00% 0.00%
Return on equity (118.82%) (87.24%) (57.72%)
Return on assets (33.02%) (68.40%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric EDIT KYTX Biotechnology median
Revenue growth (TTM) 20.83% — 5.64%
EPS growth (last fiscal year) 37.50% (9.31%) —
Revenue growth, 5-year CAGR (14.89%) — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric EDIT KYTX Biotechnology median
Debt to equity 0.00 0.15 0.00
Current ratio 3.19 9.06 4.73
Net debt to EBITDA 0.94 1.51 0.96

Dividend

Metric EDIT KYTX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric EDIT KYTX Biotechnology median
Market cap 430.03m 432.29m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack